









市場行情
/
股票
/
nasdaq-akba
/

Akebia Therapeutics Inc

AKBA

1.660USD

-0.040-2.35%

收盤 12/26, 16:00（美東）報價延遲15分鐘

440.28M總市值

虧損本益比TTM



Akebia Therapeutics Inc

1.660

-0.040-2.35%

概覽公司財務分析

概覽

公司

財務

分析

關於 Akebia Therapeutics Inc 公司

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Akebia Therapeutics Inc簡介



公司代碼AKBA

公司名稱Akebia Therapeutics Inc

上市日期Mar 20, 2014

CEOButler (John P)

員工數量181

證券類型Ordinary Share

年結日Mar 20

公司地址245 First Street

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02142

電話16178712098

網址https://akebia.com/

公司代碼AKBA

上市日期Mar 20, 2014

CEOButler (John P)

Akebia Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. John P. Butler

President, Chief Executive Officer, Director

1.68M

-17.18%

Mr. Adrian Adams

Independent Chairman of the Board

170.50K

+26.48%

Mr. Michael W. Rogers

Independent Director

131.73K

+37.18%

Ms. Cynthia Smith

Independent Director

130.93K

+37.49%

Dr. Steven C. Gilman, Ph.D.

Independent Director

122.83K

+40.97%

Dr. Myles Wolf, M.D.

Independent Director

103.38K

+52.75%

Ms. Leanne M. Zumwalt

Independent Director

79.40K

+81.69%

Mr. Nicholas (Nik) Grund

Senior Vice President, Chief Commercial Officer

45.48K

-89.72%

Mr. Erik Ostrowski

Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer

-100.00%

Dr. Steven K. Burke, M.D.

Senior Vice President - Research and Development, Chief Medical Officer

名稱

名稱/職務

職務

持股

持股變動

Mr. John P. Butler

President, Chief Executive Officer, Director

1.68M

-17.18%

Mr. Adrian Adams

Independent Chairman of the Board

170.50K

+26.48%

Mr. Michael W. Rogers

Independent Director

131.73K

+37.18%

Ms. Cynthia Smith

Independent Director

130.93K

+37.49%

Dr. Steven C. Gilman, Ph.D.

Independent Director

122.83K

+40.97%

Dr. Myles Wolf, M.D.

Independent Director

103.38K

+52.75%

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

6.30%

The Vanguard Group, Inc.

5.83%

State Street Investment Management (US)

4.46%

Geode Capital Management, L.L.C.

2.33%

Alerce Investment Management, L.P.

2.17%

其他

78.90%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

6.30%

The Vanguard Group, Inc.

5.83%

State Street Investment Management (US)

4.46%

Geode Capital Management, L.L.C.

2.33%

Alerce Investment Management, L.P.

2.17%

其他

78.90%

股東類型

持股股東

佔比

Investment Advisor

20.87%

Investment Advisor/Hedge Fund

15.27%

Hedge Fund

7.16%

Research Firm

3.64%

Individual Investor

3.57%

Private Equity

2.18%

Bank and Trust

0.37%

Pension Fund

0.29%

Insurance Company

0.03%

其他

46.61%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

322

132.23M

46.40%

+1.48M

2025Q3

319

130.76M

46.38%

+15.12M

2025Q2

289

114.82M

39.60%

+12.72M

2025Q1

262

102.34M

28.68%

+27.30M

2024Q4

243

68.25M

29.95%

+8.53M

2024Q3

241

59.59M

29.67%

+2.86M

2024Q2

231

56.74M

30.94%

-537.20K

2024Q1

275

57.32M

33.03%

-11.84M

2023Q4

274

54.98M

40.78%

+1.55M

2023Q3

287

53.47M

42.97%

+287.09K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

16.58M

6.25%

+2.61M

+18.71%

Jun 30, 2025

The Vanguard Group, Inc.

14.61M

5.51%

+1.93M

+15.18%

Jun 30, 2025

State Street Investment Management (US)

8.00M

3.02%

+1.19M

+17.50%

Jun 30, 2025

Geode Capital Management, L.L.C.

6.07M

2.29%

+1.04M

+20.75%

Jun 30, 2025

Alerce Investment Management, L.P.

5.75M

2.17%

Dec 31, 2024

Satter Muneer A

5.75M

2.17%

+5.75M

Dec 31, 2024

Renaissance Technologies LLC

4.19M

1.58%

+188.60K

+4.71%

Jun 30, 2025

Morgan Stanley & Co. LLC

4.34M

1.64%

+2.26M

+108.33%

Jun 30, 2025

Qube Research & Technologies Ltd

1.71M

0.65%

+646.27K

+60.50%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Invesco Biotechnology & Genome ETF

1.9%

Invesco NASDAQ Future Gen 200 ETF

0.38%

State Street SPDR S&P Biotech ETF

0.26%

ALPS Medical Breakthroughs ETF

0.24%

First Trust Small Cap Growth AlphaDEX Fund

0.22%

Federated Hermes MDT Small Cap Core ETF

0.18%

Direxion Daily S&P Biotech Bull 3X Shares

0.16%

iShares Micro-Cap ETF

0.11%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.08%

Fidelity Enhanced Small Cap ETF

0.08%

Invesco Biotechnology & Genome ETF

佔比1.9%

Invesco NASDAQ Future Gen 200 ETF

佔比0.38%

State Street SPDR S&P Biotech ETF

佔比0.26%

ALPS Medical Breakthroughs ETF

佔比0.24%

First Trust Small Cap Growth AlphaDEX Fund

佔比0.22%

Federated Hermes MDT Small Cap Core ETF

佔比0.18%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.16%

iShares Micro-Cap ETF

佔比0.11%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

佔比0.08%

Fidelity Enhanced Small Cap ETF

佔比0.08%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Akebia Therapeutics Inc的前五大股東是誰？



Akebia Therapeutics Inc的前五大股東如下：
BlackRock Institutional Trust Company, N.A.
持有股份：16.58M
佔總股份比例：6.25%。
The Vanguard Group, Inc.
持有股份：14.61M
佔總股份比例：5.51%。
State Street Investment Management (US)
持有股份：8.00M
佔總股份比例：3.02%。
Geode Capital Management, L.L.C.
持有股份：6.07M
佔總股份比例：2.29%。
Alerce Investment Management, L.P.
持有股份：5.75M
佔總股份比例：2.17%。